retatrutide phase 2 trial new england journal of medicine Once-Monthly Maridebart Cafraglutide for the Treatment Obesity — A Retatrutide Results: 28.3% Weight Loss
Description
Effective and controlled weight loss
GLP-1 reduces appetite and slows digestion: it's your primary hunger and satiety regulator
The studies mostly had a moderate risk of bias, limiting the validity of the conclusions
patients must meet qualifying criteria set through negotiations This is the largest potential expansion of obesity drug access in Medicaid history but its not automatic
